Astrazeneca

FromAstraZeneca ([email protected])
Subject (115)Fixed-duration Calquence plus venetoclax demonstrated superior PFS vs. standard of care in previously untreated CLL
Preheader (150)Fixed-duration Calquence plus venetoclax demonstrated superior progression-free survival vs. standard of care in previously untreated chronic lymphocy
Typography
Arial
Colors
Text Analysis
Body Words245
Subject Words15
Body Emojis1
Subject Emojis
Media Analysis
Text Links8
Image Links4
Total Links12
Images7
Technical Metrics
Performance
HTML Size, Kb
Pixel Length, px852 px
X-Spam Score-0.6
Preheader OptimizedNo
Timing
Day of WeekFriday
TimeEvening

Fixed-duration Calquence plus venetoclax demonstrated superior PFS vs. standard of care in previously untreated CLL

Fixed-duration Calquence plus venetoclax demonstrated superior progression-free survival vs. standard of care in previously untreated chronic lymphocy
Fixed-duration Calquence plus venetoclax demonstrated superior PFS vs. standard of care in previously untreated CLL